Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ANNX | PRESS-RELEASE | bullish | 6/10 | Annexon reported Q1 2026 EPS of -$0.23, beating consensus of -$0.30 by 23%, with net loss narrowing to $44.1M from $54.4 | May 7, 2026 |
| BBIO | PRESS-RELEASE | mixed | 6/10 | BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby sales, but EPS of -$ | May 7, 2026 |
| VYGR | PRESS-RELEASE | neutral | 4/10 | Voyager Therapeutics reported Q1 2026 EPS of -$0.47, beating consensus of -$0.53 by 11%, but collaboration revenue of $2 | May 7, 2026 |
| TECX | PRESS-RELEASE | neutral | 4/10 | Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by inc | May 7, 2026 |
| XENE | PRESS-RELEASE | mixed | 6/10 | Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero r | May 7, 2026 |
| CLDX | 8-K | mixed | 6/10 | Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M loss (-$0.81/share) in | May 7, 2026 |
| CRVS | 8-K | neutral | 4/10 | Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The | May 7, 2026 |
| AMRX | PRESS-RELEASE | bullish | 8/10 | Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M | May 7, 2026 |
| CLDX | PRESS-RELEASE | mixed | 6/10 | Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting wideni | May 7, 2026 |
| INMB | PRESS-RELEASE | mixed | 4/10 | INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed consensus of -$0.18 by 1 | May 7, 2026 |
| ASMB | PRESS-RELEASE | bullish | 6/10 | Assembly Biosciences reported Q1 2026 EPS of -$0.54, beating consensus of -$0.73 by 26%, while collaboration revenue fro | May 7, 2026 |
| KOD | 8-K | neutral | 4/10 | Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in lin | May 7, 2026 |
| ONCO | S-1/A | neutral | 2/10 | Onconetix filed Amendment No. 1 to its S-1 registration statement, purely to add Exhibit 5.1 (legal opinion from Ellenof | May 7, 2026 |
| RCKTW | 144 | neutral | 3/10 | Officer Sarbani Chaudhuri intends to sell 17,650 shares of RCKTW common stock (approx. $67,740) to cover tax obligations | May 7, 2026 |
| GIKLY | 6-K | mixed | 5/10 | Grifols reported Q1 2026 revenue of €1.7 billion (+3.3% cc, -4.8% reported), net profit up 21.9% to €73 million, and adj | May 7, 2026 |
| PBH | 144 | neutral | 2/10 | Officer Jeffrey Zerillo filed a Form 144 to sell 305 shares of Prestige Consumer Healthcare, valued at approximately $16 | May 7, 2026 |
| MBX | 144 | neutral | 2/10 | Former officer Richard B. Bartram filed Form 144 to sell 10,000 MBX shares (~$322,000), part of a consistent selling pat | May 7, 2026 |
| CURX | 8-K | neutral | 5/10 | Curanex Pharmaceuticals received a 180-day extension from Nasdaq until November 2, 2026, to regain compliance with the $ | May 7, 2026 |
| MBX | 8-K | bullish | 6/10 | MBX Biosciences reported Q1 2026 results with an EPS of -$0.50, beating consensus of -$0.62 by 19.4%. Net loss narrowed | May 7, 2026 |
| AARD | 8-K | bearish | 6/10 | Aardvark Therapeutics reported Q1 2026 net loss of $21.6M ($0.99 per share), missing consensus of $(0.91) by 8.8%. Both | May 7, 2026 |
| HRMY | 8-K | mixed | 5/10 | Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY), slightly below consensus of $220.8M. GAAP diluted EP | May 7, 2026 |
| EWTX | 8-K | neutral | 4/10 | Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenu | May 7, 2026 |
| WHWK | 8-K | neutral | 3/10 | Whitehawk Therapeutics reported Q1 2026 results: net loss of $22.2M ($-0.32/share) vs consensus $-0.33, a 3% beat. Reven | May 7, 2026 |
| PVLA | 8-K | bearish | 6/10 | Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and G&A expenses rose s | May 7, 2026 |
| LPCN | 8-K | bearish | 8/10 | Lipocine reported Q1 2026 results with a net loss of $3.7M ($0.54 per share), wider than the $1.9M loss in Q1 2025, driv | May 7, 2026 |
| CPRX | DEFA14A | bullish | 8/10 | Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per | May 7, 2026 |
| TOMZ | 8-K | neutral | 2/10 | TOMI Environmental Solutions filed an 8-K announcing the release of an investor presentation. The presentation content i | May 7, 2026 |
| CPRX | 8-K | bullish | 9/10 | Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per | May 7, 2026 |
| AMTX | 8-K | bearish | 7/10 | Aemetis reported Q1 2026 revenue of $54.6M, a 27% YoY increase but a 47% miss vs consensus of $103.1M. EPS of -$0.33 mis | May 7, 2026 |
| FOLD | 15-12G | neutral | 4/10 | Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin Pharmaceutica | May 7, 2026 |